238 related articles for article (PubMed ID: 35151362)
1. Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis.
Mehrabi Nejad MM; Moosaie F; Dehghanbanadaki H; Haji Ghadery A; Shabani M; Tabary M; Aryannejad A; SeyedAlinaghi S; Rezaei N
Eur J Med Res; 2022 Feb; 27(1):23. PubMed ID: 35151362
[TBL] [Abstract][Full Text] [Related]
2. Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis.
Mehrabi Nejad MM; Shobeiri P; Dehghanbanadaki H; Tabary M; Aryannejad A; Haji Ghadery A; Shabani M; Moosaie F; SeyedAlinaghi S; Rezaei N
Virol J; 2022 Aug; 19(1):132. PubMed ID: 35941646
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.
Lee ARYB; Wong SY; Chai LYA; Lee SC; Lee MX; Muthiah MD; Tay SH; Teo CB; Tan BKJ; Chan YH; Sundar R; Soon YY
BMJ; 2022 Mar; 376():e068632. PubMed ID: 35236664
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework.
Wang X; Haeussler K; Spellman A; Phillips LE; Ramiller A; Bausch-Jurken MT; Sharma P; Krivelyova A; Vats S; Van de Velde N
Front Immunol; 2023; 14():1204831. PubMed ID: 37771594
[TBL] [Abstract][Full Text] [Related]
5. Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
Obeid M; Suffiotti M; Pellaton C; Bouchaab H; Cairoli A; Salvadé V; Stevenel C; Hottinger R; Pythoud C; Coutechier L; Molinari L; Trono D; Ribi C; Gottardo R; Fenwick C; Pascual M; Duchosal MA; Peters S; Pantaleo G
JAMA Oncol; 2022 May; 8(5):e220446. PubMed ID: 35271706
[TBL] [Abstract][Full Text] [Related]
6. Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients.
Erol Ç; Yanık Yalçın T; Sarı N; Bayraktar N; Ayvazoğlu Soy E; Yavuz Çolak M; Azap Ö; Arslan H; Haberal M
Exp Clin Transplant; 2021 Dec; 19(12):1334-1340. PubMed ID: 34951350
[TBL] [Abstract][Full Text] [Related]
7. CD19+IgD+CD27- Naïve B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients.
Schulz E; Hodl I; Forstner P; Hatzl S; Sareban N; Moritz M; Fessler J; Dreo B; Uhl B; Url C; Grisold AJ; Khalil M; Kleinhappl B; Enzinger C; Stradner MH; Greinix HT; Schlenke P; Steinmetz I
Front Immunol; 2021; 12():803742. PubMed ID: 34950155
[TBL] [Abstract][Full Text] [Related]
8. A Systematic Review and Meta-Analysis of Serologic Response following Coronavirus Disease 2019 (COVID-19) Vaccination in Solid Organ Transplant Recipients.
Sakuraba A; Luna A; Micic D
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016444
[TBL] [Abstract][Full Text] [Related]
9. Poor Humoral Response in Solid Organ Transplant Recipients Following Complete mRNA SARS-CoV-2 Vaccination.
Cao J; Liu X; Muthukumar A; Gagan J; Jones P; Zu Y
Clin Chem; 2021 Dec; 68(1):251-253. PubMed ID: 34358295
[No Abstract] [Full Text] [Related]
10. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.
Becerril-Gaitan A; Vaca-Cartagena BF; Ferrigno AS; Mesa-Chavez F; Barrientos-Gutiérrez T; Tagliamento M; Lambertini M; Villarreal-Garza C
Eur J Cancer; 2022 Jan; 160():243-260. PubMed ID: 34794855
[TBL] [Abstract][Full Text] [Related]
11. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.
Galmiche S; Luong Nguyen LB; Tartour E; de Lamballerie X; Wittkop L; Loubet P; Launay O
Clin Microbiol Infect; 2022 Feb; 28(2):163-177. PubMed ID: 35020589
[TBL] [Abstract][Full Text] [Related]
12. Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis.
Verleye A; Wijtvliet V; Abrams S; Hellemans R; Bougrea R; Massart A; Pipeleers L; Wissing KM; Ariën KK; De Winter BY; Van Damme P; Abramowicz D; Ledeganck KJ
Nephrol Dial Transplant; 2022 Jul; 37(8):1566-1575. PubMed ID: 35544087
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.
Noori M; Azizi S; Abbasi Varaki F; Nejadghaderi SA; Bashash D
Int Immunopharmacol; 2022 Sep; 110():109046. PubMed ID: 35843148
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity.
Jaycox JR; Lucas C; Yildirim I; Dai Y; Wang EY; Monteiro V; Lord S; Carlin J; Kita M; Buckner JH; Ma S; Campbell M; Ko A; Omer S; Lucas CL; Speake C; Iwasaki A; Ring AM
Nat Commun; 2023 Mar; 14(1):1299. PubMed ID: 36894554
[TBL] [Abstract][Full Text] [Related]
15. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.
Kreuzberger N; Hirsch C; Andreas M; Böhm L; Bröckelmann PJ; Di Cristanziano V; Golinski M; Hausinger RI; Mellinghoff S; Lange B; Lischetzki T; Kappler V; Mikolajewska A; Monsef I; Park YS; Piechotta V; Schmaderer C; Stegemann M; Vanshylla K; Weber F; Weibel S; Stephani C; Skoetz N
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015021. PubMed ID: 35943061
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis.
Li Z; Liu S; Li F; Li Y; Li Y; Peng P; Li S; He L; Liu T
Front Immunol; 2022; 13():965971. PubMed ID: 36177017
[TBL] [Abstract][Full Text] [Related]
17. Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort.
Zecca E; Rizzi M; Tonello S; Matino E; Costanzo M; Rizzi E; Casciaro GF; Manfredi GF; Acquaviva A; Gagliardi I; Calzaducca E; Mallela VR; D'Onghia D; Minisini R; Bellan M; Castello LM; Gavelli F; Avanzi GC; Patrucco F; Chiocchetti A; Pirisi M; Rigamonti C; Lilleri D; Sola D; Sainaghi PP
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016388
[TBL] [Abstract][Full Text] [Related]
18. Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants.
Qu P; Faraone JN; Evans JP; Zheng YM; Yu L; Ma Q; Carlin C; Lozanski G; Saif LJ; Oltz EM; Gumina RJ; Liu SL
N Engl J Med; 2022 Oct; 387(14):1329-1331. PubMed ID: 36069925
[No Abstract] [Full Text] [Related]
19. COVID-19 Vaccination in Patients With Malignancy; A Systematic Review and Meta-Analysis of the Efficacy and Safety.
Javadinia SA; Alizadeh K; Mojadadi MS; Nikbakht F; Dashti F; Joudi M; Harati H; Welsh JS; Farahmand SA; Attarian F
Front Endocrinol (Lausanne); 2022; 13():860238. PubMed ID: 35586627
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant: A Systematic Review and Meta-Analysis.
Manothummetha K; Chuleerarux N; Sanguankeo A; Kates OS; Hirankarn N; Thongkam A; Dioverti-Prono MV; Torvorapanit P; Langsiri N; Worasilchai N; Moonla C; Plongla R; Garneau WM; Chindamporn A; Nissaisorakarn P; Thaniyavarn T; Nematollahi S; Permpalung N
JAMA Netw Open; 2022 Apr; 5(4):e226822. PubMed ID: 35412626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]